CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) and Spero Therapeutics (NASDAQ:SPRO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Risk & Volatility
CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.
Valuation and Earnings
This table compares CASI Pharmaceuticals and Spero Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CASI Pharmaceuticals | $26.85 million | 0.10 | -$39.26 million | ($3.01) | -0.07 |
| Spero Therapeutics | $66.80 million | 1.06 | $8.57 million | $0.11 | 11.05 |
Spero Therapeutics has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings for CASI Pharmaceuticals and Spero Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CASI Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
| Spero Therapeutics | 0 | 2 | 0 | 0 | 2.00 |
CASI Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals’ higher possible upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Spero Therapeutics.
Profitability
This table compares CASI Pharmaceuticals and Spero Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CASI Pharmaceuticals | -183.93% | N/A | -131.54% |
| Spero Therapeutics | 24.90% | 16.17% | 12.57% |
Summary
Spero Therapeutics beats CASI Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
About Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
